Business Wire

Sharjah Ruler Launches First 17 Volumes of ‘Historical Corpus of the Arabic Language’

Share

A historical cultural feat for the Arab world has been attained, as His Highness Sheikh Dr. Sultan bin Muhammad Al Qasimi, Member of the Supreme Council and Ruler of Sharjah, released the first 17 volumes of the Historical Corpus of the Arabic Language – the first-of-its kind project to chronicle 17 centuries of development in the Arabic language, in the presence of His Highness Sheikh Sultan bin Ahmed Al Qasimi, Crown Prince and Deputy Ruler of Sharjah.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211103005884/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

HH Ruler of Sharjah signs the copies of ‘Historical Corpus of the Arabic Language’ at the Sharjah International Book Fair (Photo: AETOSWire)

The Corpus volumes were unveiled by the Sharjah Ruler during the opening ceremony of the 40th edition of the Sharjah International Book Fair (SIBF) on Tuesday (2 November) at Expo Centre Sharjah, in the presence of a host of Arab ministers, presidents of Arabic language academies in the region and several Arabic scholars and researchers. HH Ruler of Sharjah also unveiled the official website of The Historical Corpus of the Arabic Language on this occasion.

In his keynote address, the Sharjah Ruler noted: “Arabic is one of the oldest living languages. We are here to celebrate Arabic language experts who gathered to work for years to document the roots and meanings of the Arabic language alphabet. We have started to work hard and bridge the gaps that existed in the documentation of the language. Finally, the sun has risen on this beautiful Corpus, which is the fruit of the efforts of a number of Arabic language institutions across the region.”

He added: “The role this detailed corpus will play in informing and educating students, researchers, and linguists and even the everyday language enthusiasts will be immense. I am not exaggerating when I say that there has been no other project that has attracted my attention or the attention of the Arab linguist community in our region to the extent that this project has. I am following up on the development of the efforts of everyone involved in this project, and I assure you that in the coming years we will be publishing several more volumes. I thank each and everyone involved in making this project a success.”

The Sharjah Ruler spoke about the online platform and smart phone applications that have been designed to make the Historical Corpus available digitally, and facilitate easy access to these resources from anywhere in the world. He also signed the copies of the first edition of the Historical Corpus of the Arabic Language at the SIBF 2021 opening ceremony.

The first volumes of the corpus are dedicated to the first five Arabic letters: the Hamza, ba, ta, tha and jeem and outline their evolution throughout the pre-Islamic period, the Islamic era from 1 AH to 132 AH, the Abbasid Caliphate from 133 AH to 656 AH, and the modern-day era from 1214 AH to date.

Dedicated website

The website dedicated to the Historical Corpus of the Arabic Language will offer scholars, linguists, researchers and language enthusiasts access to the 17 volumes of the corpus from anywhere in the world.

Champions of the Arabic language from across the region joined hands

The corpus has seen the collaboration of hundreds of researchers and linguists, editors and experts from 10 Arabic language academies across the Arab world, under the supervision of the Union of Arab Scientific Language Academies in Cairo, Egypt, and with the Arabic Language Academy in Sharjah managing the project’s executive committee. The corpus relies on a database of sources collected and digitised over the last four years, comprising 20,000 Arabic books, manuscripts, sources, and historical documents, including old inscriptions and archaeological finds.

The Historical Corpus of the Arabic Language is dedicated to providing key information about the history of Arabic lexicon, the original root of each word and all other words that are derived from the root with their vocal and phonetic changes. It traces the history of a given word and identifies the first user and evolution of that word from pre-Islamic Arabia all the way to the modern time. In this respect, it is different from any other dictionary because it cites living verses of the Holy Quran and Hadith of the Prophet, peace be upon him.

It also reveals the development of Arabic idioms and expressions through the centuries, and documents the entry of new words into Arabic language, lists words that are no longer used, and explains the reasons why. Besides, the corpus reviews the development of arts and sciences that directly relate to linguistics including grammar, morphology, philology, phonetics, rhetoric, rhyme, and so on.

It also offers comparative lexical reviews on Arabic and the influence it had on other Semitic languages such as Hebrew, Akkadian, Syriac, Abyssinian, and Amharic. An expert committee outlined the similarities and differences between Arabic words and the equivalent words in those languages, citing examples and documenting the bibliography and reference books that were used in the project.

Several senior officials were present during the launch, including Sheikh Nahyan bin Mubarak Al Nahyan, UAE Minister of Tolerance and Coexistence; Bodour Al Qasimi, President of the International Publishers Association; Sheikha Hoor Al Qasimi, President of the Sharjah Art Foundation; Sheikh Khalid bin Issam Al Qasimi, Chairman of the Department of Civil Aviation in Sharjah; Sheikh Salem bin Abdulrahman Al Qasimi, Chairman of the Sharjah Ruler's Office; Sheikha Nawar bint Ahmed Al Qasimi, Director, SAF; Abdul Rahman bin Mohammad Al Owais, UAE Minister of Health and Prevention.

The launch of the corpus’s 17 volumes was also witnessed by Dr. Salah Fadl, President of the Arab Language Academy in Cairo; Dr. Mamoun Wajeeh, Scientific Manager of the Historical Corpus of the Arabic Language; Dr. Abdulhamid Madkour, Secretary General of the Union of Arab Scientific Language Academies, and Secretary-General of the Arabic Language Academy in Cairo.

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Hussain Al Mulla
Email: hussain.almulla@sgmb.ae
Phone: +97156 3980067

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye